Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study

Core Insights - Quoin Pharmaceuticals Ltd. announced positive initial clinical data from its ongoing Investigator Pediatric Peeling Skin Syndrome clinical study, showing significant skin healing after 12 weeks of treatment with QRX003 [1][4]. Clinical Study Results - After 12 weeks of treatment, the Modified Ichthyosis Area of Severity Index (M-IASI) score improved from 36 to 12, indicating a significant reduction in skin symptoms [2]. - The Investigator's Global Assessment (IGA) score improved from 4 (Severe) to 2 (Mild), demonstrating a clinically meaningful improvement [2][5]. - The Children's Dermatology Life Quality Index (CDQLI) score decreased from 19 to 11, reflecting a positive impact on the patient's quality of life [2][5]. Treatment Tolerance and Future Plans - QRX003 has been well tolerated by the patient, with no adverse events reported, and the patient is expected to continue treatment with further assessments scheduled after 24 weeks [4][5]. - The company plans to expand the study to include additional pediatric subjects in other countries and advance the clinical development of QRX003 for Peeling Skin Syndrome [5][6]. Company Overview - Quoin Pharmaceuticals Ltd. is focused on developing therapeutic products for rare and orphan diseases, with a pipeline that includes treatments for various conditions such as Netherton Syndrome and Peeling Skin Syndrome [8].